Pharmacological management of psychosis in Parkinson disease: A review

Danish Bhatti, Diego Torres-Russotto

Research output: Contribution to journalReview articlepeer-review


Psychosis in Parkinson Disease (PDP) is a common clinical problem and presents a pharmacological therapeutic conundrum. Many patients with PDP require anti-parkinsonian drugs for motor control, but the use of these medications has been associated with worsening of the psychotic symptoms. Differences from other psychotic disorders include the association with the use of anti-parkinsonian drugs, and the common presentation with visual hallucinations. Understanding of the pathophysiology of this phenomenon in PD has grown over the last few decades with the realization that the dopaminergic system is not the sole player. This has led to pharmacological research beyond antipsychotics. In this article we review the general management of PDP, the available evidence for the pharmacological management of PDP, and the medications profile and safety. Useful tables, practical recommendations and treatment algorithm are proposed.

Original languageEnglish (US)
Pages (from-to)151-163
Number of pages13
JournalCurrent Drug Therapy
Issue number3
StatePublished - 2012


  • Atypical antipsychotics
  • Cholinesterase inhibitors
  • Dopamine agonists
  • Levodopa
  • Parkinson disease
  • Psychosis
  • Psychosis in parkinson disease
  • Review
  • Side effects

ASJC Scopus subject areas

  • General Pharmacology, Toxicology and Pharmaceutics
  • Pharmacology (medical)


Dive into the research topics of 'Pharmacological management of psychosis in Parkinson disease: A review'. Together they form a unique fingerprint.

Cite this